 |
PNPURE™
Polynucleotide Dermal Filler — PNPURE™ is a clinically designed injectable intended to rebuild skin structure from within. Engineered from high‑molecular‑weight polynucleotides and refined using our proprietary PUNEXT™ purification, PNPURE™ supports deep dermal regeneration, sustained hydration, and measurable improvement in skin quality with a safety profile tailored for aesthetic clinics and discerning patients.
PNPURE™ begins with responsibly farmed Pacific salmon DNA harvested from clean waters near 35°N latitude. The source selection, combined with antibiotic‑free aquaculture practices, ensures a biologically consistent raw material with high human DNA homology that promotes favorable biocompatibility.
Our PUNEXT™ multi‑stage purification removes proteins and impurities, producing polynucleotides that meet stringent purity thresholds (>99%). This high level of purity reduces immunogenic risk and improves predictable clinical performance across treatment areas.
PNPURE™ polynucleotides are manufactured to a targeted molecular weight range (1260–1570 kDa). This larger molecular architecture supports formation of a stable three‑dimensional matrix within the dermis, enhancing structural support and prolonging regenerative signaling compared with lower molecular weight preparations.
Intended Use: Full‑face dermal revitalization and post‑procedural support.
PN Concentration: 25 mg/mL (2.5%).
Molecular Weight: 1260–1570 kDa.
Presentation: 3 mL prefilled syringe; 30G needle.
NeoSkin delivers a higher PN payload to accelerate extracellular matrix remodeling, supporting collagen and elastin restoration and delivering durable improvements in skin texture and firmness.
Intended Use: Delicate periorbital rejuvenation and skin nourishment.
PN Concentration: 10 mg/mL.
Molecular Weight: 1260–1570 kDa.
Complementary Actives: Hyaluronic acid, multi‑amino acid complex, and creatine for hydration, nutrient support, and antioxidant defense.
Presentation: 1 mL prefilled syringe; 30G needle.
NeoEye combines a gentler PN dose with synergistic hydrating and metabolic cofactors to minimize local irritation while enhancing elasticity and brightness in the sensitive eye area.
Upon intradermal deposition, high‑molecular‑weight polynucleotides create a transient, supportive scaffold that restores the dermal microenvironment and improves tissue turgor.
PNs act as biologically active polymers that modulate local fibroblast activity, upregulating collagen and elastin synthesis while improving endogenous hyaluronic acid retention — a coordinated process that enhances dermal thickness and resilience.
Early (2–4 days): Noticeable improvement in skin smoothness and hydration.
Intermediate (2–3 weeks): Increased firmness, reduced fine lines, and improved skin clarity as matrix remodeling accelerates.
Cumulative (after multiple sessions): Enhanced lifting effect, fuller contour, and sustained dermal quality attributable to reinforced dermal architecture.
These effects make PNPURE™ suitable both as a stand‑alone regenerative treatment and as an adjunct to traditional aesthetic procedures.
Internal preclinical and clinical evaluations indicate that PNPURE™ activates fibroblast proliferation and promotes structural dermal improvements that persist beyond the acute post‑treatment period. In comparative assessments against standard non‑crosslinked hyaluronic acid products, PNPURE™ demonstrates earlier regenerative signaling and sustained histologic improvements in dermal organization. These data support its role as a durable, tissue‑centric option for clinics seeking regenerative outcomes rather than transient volumization alone.
PNPURE™ is intended for intradermal injection by trained medical professionals. The product’s high purity and controlled molecular profile minimize adverse responses, but standard aseptic technique and appropriate patient assessment remain essential. Needle size and injection depth should be selected per treatment area and clinical objectives.
A typical regimen includes a series of 2–4 sessions spaced according to treatment goals and patient response. NeoSkin is appropriate for full‑face regenerative protocols, while NeoEye is designed for periorbital skin quality restoration and maintenance. Combination approaches with conservative HA fillers or energy‑based devices can be considered to address volumetric deficits alongside tissue regeneration.
PNPURE™ delivers a science‑driven balance of purity, molecular optimization, and clinical utility. For aesthetic clinics and patients seeking natural‑looking skin renewal—improved texture, hydration, and resiliency—PNPURE™ offers a regenerative pathway that addresses the root causes of dermal aging rather than superficially masking them.
Click here to contact our sales team to request technical dossiers, clinical summaries, or volume pricing. Discover how integrating PNPURE™ polynucleotide dermal filler into your treatment menu can improve patient satisfaction, differentiate your practice, and deliver repeatable regenerative results.
Polynucleotide Dermal Filler — PNPURE™ is a clinically designed injectable intended to rebuild skin structure from within. Engineered from high‑molecular‑weight polynucleotides and refined using our proprietary PUNEXT™ purification, PNPURE™ supports deep dermal regeneration, sustained hydration, and measurable improvement in skin quality with a safety profile tailored for aesthetic clinics and discerning patients.
PNPURE™ begins with responsibly farmed Pacific salmon DNA harvested from clean waters near 35°N latitude. The source selection, combined with antibiotic‑free aquaculture practices, ensures a biologically consistent raw material with high human DNA homology that promotes favorable biocompatibility.
Our PUNEXT™ multi‑stage purification removes proteins and impurities, producing polynucleotides that meet stringent purity thresholds (>99%). This high level of purity reduces immunogenic risk and improves predictable clinical performance across treatment areas.
PNPURE™ polynucleotides are manufactured to a targeted molecular weight range (1260–1570 kDa). This larger molecular architecture supports formation of a stable three‑dimensional matrix within the dermis, enhancing structural support and prolonging regenerative signaling compared with lower molecular weight preparations.
Intended Use: Full‑face dermal revitalization and post‑procedural support.
PN Concentration: 25 mg/mL (2.5%).
Molecular Weight: 1260–1570 kDa.
Presentation: 3 mL prefilled syringe; 30G needle.
NeoSkin delivers a higher PN payload to accelerate extracellular matrix remodeling, supporting collagen and elastin restoration and delivering durable improvements in skin texture and firmness.
Intended Use: Delicate periorbital rejuvenation and skin nourishment.
PN Concentration: 10 mg/mL.
Molecular Weight: 1260–1570 kDa.
Complementary Actives: Hyaluronic acid, multi‑amino acid complex, and creatine for hydration, nutrient support, and antioxidant defense.
Presentation: 1 mL prefilled syringe; 30G needle.
NeoEye combines a gentler PN dose with synergistic hydrating and metabolic cofactors to minimize local irritation while enhancing elasticity and brightness in the sensitive eye area.
Upon intradermal deposition, high‑molecular‑weight polynucleotides create a transient, supportive scaffold that restores the dermal microenvironment and improves tissue turgor.
PNs act as biologically active polymers that modulate local fibroblast activity, upregulating collagen and elastin synthesis while improving endogenous hyaluronic acid retention — a coordinated process that enhances dermal thickness and resilience.
Early (2–4 days): Noticeable improvement in skin smoothness and hydration.
Intermediate (2–3 weeks): Increased firmness, reduced fine lines, and improved skin clarity as matrix remodeling accelerates.
Cumulative (after multiple sessions): Enhanced lifting effect, fuller contour, and sustained dermal quality attributable to reinforced dermal architecture.
These effects make PNPURE™ suitable both as a stand‑alone regenerative treatment and as an adjunct to traditional aesthetic procedures.
Internal preclinical and clinical evaluations indicate that PNPURE™ activates fibroblast proliferation and promotes structural dermal improvements that persist beyond the acute post‑treatment period. In comparative assessments against standard non‑crosslinked hyaluronic acid products, PNPURE™ demonstrates earlier regenerative signaling and sustained histologic improvements in dermal organization. These data support its role as a durable, tissue‑centric option for clinics seeking regenerative outcomes rather than transient volumization alone.
PNPURE™ is intended for intradermal injection by trained medical professionals. The product’s high purity and controlled molecular profile minimize adverse responses, but standard aseptic technique and appropriate patient assessment remain essential. Needle size and injection depth should be selected per treatment area and clinical objectives.
A typical regimen includes a series of 2–4 sessions spaced according to treatment goals and patient response. NeoSkin is appropriate for full‑face regenerative protocols, while NeoEye is designed for periorbital skin quality restoration and maintenance. Combination approaches with conservative HA fillers or energy‑based devices can be considered to address volumetric deficits alongside tissue regeneration.
PNPURE™ delivers a science‑driven balance of purity, molecular optimization, and clinical utility. For aesthetic clinics and patients seeking natural‑looking skin renewal—improved texture, hydration, and resiliency—PNPURE™ offers a regenerative pathway that addresses the root causes of dermal aging rather than superficially masking them.
Click here to contact our sales team to request technical dossiers, clinical summaries, or volume pricing. Discover how integrating PNPURE™ polynucleotide dermal filler into your treatment menu can improve patient satisfaction, differentiate your practice, and deliver repeatable regenerative results.
